<DOC>
	<DOCNO>NCT00966940</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Travoprost 0.004 % Tafluprost 0.0015 % patient primary open angle glaucoma ocular hypertension medication administer evening .</brief_summary>
	<brief_title>Efficacy Safety Travoprost 0.004 % Versus Tafluprost 0.0015 % Patients With Primary Open-angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>An ECreviewed approve ( use study ) inform consent form must read , sign , date participate patient well sign date individual ( Principal Investigator site personnel ) obtain informed consent , conduct Screening Visit prior initiation study procedure . Patients must least 21 year age . Must able follow instruction willing able attend require study visit . Must clinical diagnosis ocular hypertension primary openangle glaucoma least one eye ( qualify eye ) . Currently treated patient , investigator 's judgment , require change treatment reason improve efficacy , tolerability compliance . Must IOP consider safe , eye , way assure clinical stability vision optic nerve throughout trial . Must intraocular pressure &gt; 21 mm Hg least one eye 08:00 &gt; 19 mm Hg eye 16:00 , &lt; 35 mm Hg eye diurnal time point Visit 2 . Must best correct visual acuity 6/60 ( 20/200 Snellen ) good eye . Other protocoldefined inclusion criterion may apply . Presence primary secondary glaucoma list inclusion criterion . Presence extreme narrow angle complete partial closure either eye , measure gonioscopy ( occludable angle treat patent iridectomy acceptable ) . Any abnormality prevent reliable applanation tonometry qualify eye ( ) . Any opacity patient uncooperativeness restricts adequate examination ocular fundus anterior chamber either eye . Concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye . Blepharitis nonclinically significant conjunctival injection allow . Intraocular conventional surgery laser surgery qualify eye ( ) less three month prior Visit 1 . Risk visual field visual acuity worsen consequence participation trial , investigator 's best judgment . Progressive retinal optic nerve disease cause apart glaucoma . Women childbearing potential use reliable mean birth control , pregnant lactating female . Any clinically significant , serious , severe medical psychiatric condition . A condition , opinion investigator , would interfere optimal participation study , would present special risk patient . Participation investigational study within 30 day prior Visit 2 . Known medical history allergy sensitivity component preparation use trial deem clinically significant opinion investigator . Use systemic medication know affect IOP ( e.g. , oral betaadrenergic blocker , alphaagonists blocker , angiotensin convert enzyme inhibitor calcium channel blocker ) , stable course 7 day prior Visit 2 anticipated change dosage course study . Anticipated use systemic corticosteroid , route except inhale , great two week trial . A history , risk uveitis cystoid macular edema ( CME ) . History ocular herpes simplex . Unwillingness accept risk iris , skin , eyelash change associate prostaglandin therapy . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>IOP</keyword>
	<keyword>Travoprost</keyword>
</DOC>